NASDAQ:GERN

Geron Stock Forecast, Price & News

$1.96

+0.55 (+39.01 %)

(As of 06/18/2021 02:03 PM ET)

Add

Compare

Today's Range

$1.52

▼

$2.22

50-Day Range

$1.25

▼

$1.52

52-Week Range

$1.22

▼

$2.36

Volume8.63 million shs

Average Volume2.94 million shs

Market Capitalization$624.39 million

P/E RatioN/A

Dividend YieldN/A

Beta1.12

30 days | 90 days | 365 days | Advanced Chart

Receive GERN News and Ratings via Email

Sign-up to receive the latest news and ratings for Geron and its competitors with MarketBeat's FREE daily newsletter.

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

Russia monitoring talk of Turkish military base in Azerbaijan, says Kremlin - Yahoo Finance
June 18, 2021 | finance.yahoo.com

Hot Stocks: BMY collaboration, CAI merger deal, GERN pops on clinical trial - Seeking Alpha
June 18, 2021 | seekingalpha.com

Why Geron Stock Is Soaring Today
June 18, 2021 | finance.yahoo.com

Geron, AnPac Bio-Medical Science leads healthcare gainers; Orphazyme, Athira Pharma among major losers
June 18, 2021 | seekingalpha.com

Geron Announces Publication of IMbark Phase 2 Data in Journal of Clinical Oncology - Yahoo Finance
June 18, 2021 | finance.yahoo.com

Geron Announces Publication of IMbark Phase 2 Data in Journal of Clinical Oncology - Business Wire
June 17, 2021 | businesswire.com

Geron Reports Two Presentations at Virtual European Hematology Association Annual Congress - Business Wire
June 14, 2021 | businesswire.com

Geron Reports Two Presentations at Virtual European Hematology Association Annual Congress
June 14, 2021 | finance.yahoo.com

UK's Frost says no breakthroughs in EU talks over Northern Ireland - Reuters UK
June 9, 2021 | reuters.com

Geron: Return On Capital Employed Insights - Benzinga
June 8, 2021 | benzinga.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:GERN
Previous Symbol
CUSIP37416310
CIK886744
Webwww.geron.com
Phone650-473-7700
Employees53
Year FoundedN/A

Sales & Book Value

Annual Sales$250,000.00
Price / Sales2,497.57
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.68 per share
Price / Book2.88

Profitability

EPS (Most Recent Fiscal Year)($0.28)
Net Income$-75,620,000.00
Net Margins-25,765.09%
Return on Equity-38.89%
Return on Assets-31.96%

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares318,568,000
Market Cap$624.39 million
Next Earnings Date8/5/2021 (Estimated)
OptionableOptionable

MarketRank^™

Overall MarketRank^™

1.53 out of 5 stars

Medical Sector

538th out of 2,100 stocks

Pharmaceutical Preparations Industry

258th out of 831 stocks

3.5 Analyst's Opinion

Consensus Rating
Geron has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $5.00, Geron has a forecasted upside of 130.4% from its current price of $2.17.
Amount of Analyst Coverage
Geron has only been the subject of 1 research reports in the past 90 days.

2.7 Community Rank

Outperform Votes
Geron has received 452 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Geron has received 386 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Geron has received 53.94% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Geron and other stocks. Vote “Outperform” if you believe GERN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe GERN will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Geron does not currently pay a dividend.
Dividend Growth
Geron does not have a long track record of dividend growth.

0.8 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Geron insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 5.90% of the stock of Geron is held by insiders.
Percentage Held by Institutions
45.12% of the stock of Geron is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Geron are expected to grow in the coming year, from ($0.36) to ($0.34) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Geron is -7.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Geron is -7.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Geron has a P/B Ratio of 3.19. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Geron (NASDAQ:GERN) Frequently Asked Questions

Is Geron a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Geron in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Geron stock.
View analyst ratings for Geron or view top-rated stocks.

What stocks does MarketBeat like better than Geron?

Wall Street analysts have given Geron a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Geron wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Geron's next earnings date?

Geron is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Geron.

How were Geron's earnings last quarter?

Geron Co. (NASDAQ:GERN) announced its quarterly earnings data on Sunday, May, 9th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.08) by $0.01. The biopharmaceutical company earned $0.14 million during the quarter, compared to analyst estimates of $0.08 million. Geron had a negative trailing twelve-month return on equity of 38.89% and a negative net margin of 25,765.09%.
View Geron's earnings history.

How has Geron's stock price been impacted by COVID-19?

Geron's stock was trading at $1.03 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, GERN stock has increased by 77.7% and is now trading at $1.83.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for GERN?

3 analysts have issued twelve-month price targets for Geron's shares. Their forecasts range from $3.00 to $7.00. On average, they expect Geron's share price to reach $5.00 in the next twelve months. This suggests a possible upside of 173.2% from the stock's current price.
View analysts' price targets for Geron or view top-rated stocks among Wall Street analysts.

Who are Geron's key executives?

Geron's management team includes the following people:

Dr. John A. Scarlett, CEO, Pres & Chairman (Age 70, Pay $1.39M)
Ms. Olivia Kyusuk Bloom, Exec. VP of Fin., CFO & Treasurer (Age 52, Pay $761.54k)
Dr. Andrew J. Grethlein, Exec. VP & COO (Age 57, Pay $791.52k)
Ms. Melissa A. Kelly Behrs, Exec. VP & Chief Bus. Officer (Age 57, Pay $764.81k)
Dr. Aleksandra Rizo M.D., Ph.D., Exec. VP & Chief Medical Officer (Age 46, Pay $892.29k)
Ms. Suzanne Messere, Head of Investor Relations & Corp. Communications
Mr. Stephen N. Rosenfield, Exec. VP, Chief Legal Officer & Corp. Sec. (Age 71)
Ms. Shannon Odam, VP of HR
Mr. Anil Kapur, Chief Commercial Officer & Exec. VP of Corp. Strategy (Age 51)

What is John A. Scarlett's approval rating as Geron's CEO?

5 employees have rated Geron CEO John A. Scarlett on Glassdoor.com. John A. Scarlett has an approval rating of 82% among Geron's employees.

Who are some of Geron's key competitors?

Some companies that are related to Geron include Amgen (AMGN), Gilead Sciences (GILD), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Exact Sciences (EXAS), Alnylam Pharmaceuticals (ALNY), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Novavax (NVAX), Repligen (RGEN), Neurocrine Biosciences (NBIX) and United Therapeutics (UTHR).
View all of GERN's competitors.

What other stocks do shareholders of Geron own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Geron investors own include Novavax (NVAX), Dynavax Technologies (DVAX), Matinas BioPharma (MTNB), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), Rigel Pharmaceuticals (RIGL), Chesapeake Energy (CHKAQ), OrganiGram (OGI), SCYNEXIS (SCYX) and Bionano Genomics (BNGO).

What is Geron's stock symbol?

Geron trades on the NASDAQ under the ticker symbol "GERN."

Who are Geron's major shareholders?

Geron's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.31%), Geode Capital Management LLC (1.53%), Northern Trust Corp (0.95%), Great Point Partners LLC (0.82%), Morgan Stanley (0.40%) and Millennium Management LLC (0.39%).
View institutional ownership trends for Geron.

Which major investors are selling Geron stock?

GERN stock was sold by a variety of institutional investors in the last quarter, including Great Point Partners LLC, Millennium Management LLC, D. E. Shaw & Co. Inc., Credit Suisse AG, Northern Trust Corp, GSA Capital Partners LLP, Goldman Sachs Group Inc., and Summit X LLC.
View insider buying and selling activity for Geron or view top insider-selling stocks.

Which major investors are buying Geron stock?

GERN stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Citigroup Inc., Rafferty Asset Management LLC, UBS Group AG, Geode Capital Management LLC, Morgan Stanley, Squarepoint Ops LLC, and Barclays PLC.
View insider buying and selling activity for Geron or or view top insider-buying stocks.

How do I buy shares of Geron?

Shares of GERN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Geron's stock price today?

One share of GERN stock can currently be purchased for approximately $1.83.

How much money does Geron make?

Geron has a market capitalization of $582.98 million and generates $250,000.00 in revenue each year. The biopharmaceutical company earns $-75,620,000.00 in net income (profit) each year or ($0.28) on an earnings per share basis.

How many employees does Geron have?

Geron employs 53 workers across the globe.

What is Geron's official website?

The official website for Geron is www.geron.com.

Where are Geron's headquarters?

Geron is headquartered at 919 EAST HILLSDALE BOULEVARD SUITE 250, FOSTER CITY CA, 94404.

How can I contact Geron?

Geron's mailing address is 919 EAST HILLSDALE BOULEVARD SUITE 250, FOSTER CITY CA, 94404. The biopharmaceutical company can be reached via phone at 650-473-7700 or via email at [email protected]

This page was last updated on 6/18/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here